Short-Term Results of Endovenous Laser Ablation in Our Institute: One-Year Experience

Abstract

After the endovenous laser ablation (EVLA) procedure with a 980-nm diode laser was approved by the Japanese National Health Insurance in 2011, our institute has primarily performed EVLA for primary varicose vein treatment. In the present retrospective study, we assess the short-term results of EVLA in our institute. Between April 2004 and May 2013, we have performed EVLA in 71 limbs and great saphenous vein (GSV) stripping in 104 limbs. Overall, we noted that EVLA treatment for patients with primary varicose veins yielded sufficient satisfaction rates as compared to conventional GSV stripping surgery. In particular, EVLA has advantages such as the decreased risk of massive bleeding from the major venous branch at the saphenofemoral junction and lower wound infection rates. However, we believe that the surgical treatment strategy should be carefully chosen while considering the findings and condition of each patient to achieve a favorable result.